CURRICULUM VITAE



CURRICULUM VITAENORMAN J. KACHUCK, M.D.A.Personal InformationHome Address12631 Addison StreetValley Village, California 91607Home Phone(818) 753-9639Business Phone(323) 217-2125Email Addressnkachuck@usc.eduDate of BirthApril 21, 1955Place of BirthNew York, New YorkCitizenshipUnited States of AmericaB.EducationHigh SchoolFoothill High School, Tustin, California, 6/69 to 6/72 Degree granted 3/73 UniversitiesUniversity of La Verne, La Verne, California, 9/72 to 2/73University of California at Irvine, Irvine, California, 3/73 to 6/73University of California at San Diego. San Diego, California. B.A. Musical composition and performance. Graduated Cum Laude, Provost’s Honor List. 6/73 to 6/77Juilliard School, 1978 - withdrawnUniversity of California at Los Angeles. Los Angeles, California. Postbaccalaureate premedical studies. 9/80 to 6/83Medical SchoolUniversity of Southern California School of Medicine. Los Angeles, California. 9/83 to 6/87 M.D. granted 6/15/87InternshipLAC+USC Medical Center Internal Medicine. Los Angeles, California. 7/87 to 6/88ResidencyLAC+USC Medical Center Department of Neurology. Los Angeles, California. 7/88 to 6/91Honors and AwardsSt. Vincent Fellowship. St. Vincent's Hospital. 1988AOA 1998-LicensureState of California license number G 63328. 1988Board CertificationBoard Certified, American Academy of Psychiatry and Neurology, Inc. Neurology, 1993Additional TrainingCertificate in Management Development Course for Physicians, USC School of Business Administration, 1996Academic AppointmentsAssistant Professor of Clinical Neurology, University of Southern California School of Medicine. Los Angeles, California. 1991-1997Associate Professor of Clinical Neurology, University of Southern California School of Medicine. Los Angeles, California. 1997-2010C.Professional BackgroundSpecific Teaching ResponsibilitiesUniversity of Southern California:Lecturer, Neurologic Problems of Performing Artists. USC School of Music. 1992-1995University of Southern California Keck School of Medicine:Lecturer, Neurological DisordersUSC Department of Occupational Therapy. 1990-92Lecturer, Introduction to Neurologic EvaluationUSC Department of Occupational Therapy. 1992-2010Multiple Sclerosis in the ElderlyUSC Department of Geriatric Medicine Grand RoundsLos Angeles, CaliforniaOctober 11, 1993Moderator and OrganizerSymposium on Cognitive Issues in Multiple SclerosisUniversity of Southern California School of MedicineLos Angeles, CaliforniaApril 20, 1996Member, USC Pain Management Service. 1993-1997MS Research Update Annual SymposiumUniversity of Southern California School of MedicineLos Angeles, CaliforniaSponsored by: Biogen Idec, Inc. 1998-2005Moderator, MS Therapy into the Next MillenniumUniversity of Southern California School of MedicineLos Angeles, CaliforniaSponsored by: TEVA Marion August 21, 1999Invited Lecturer, Multiple Sclerosis and the Autoimmune DilemmaThe Sixth Annual Joseph P. van der Meulen SymposiumUniversity of Southern California School of MedicineLos Angeles, CaliforniaMarch 26, 1999Lecturer, Multiple Sclerosis and Demyelinating Diseases Core Grand Rounds Course, Department of Internal Medicine, 2000-2008Moderator, Morning Session, The Tenth Joseph P van der Meulen Symposium in Clinical NeurosciencesMarch, 2003(Professional Background - Continued)University of Southern California School of PharmacyLecturer, Treatment Strategies for Central Nervous System Inflammatory Diseases. 2002-2010USC Department of Internal MedicineAnnual Review Course“New Trends in Multiple Sclerosis”2002-2006USC Keck School of Medicine Department of NeurologyDirector, MS Comprehensive Care Center. 1998-2010Clinical Co-Chief, Neuroimmunology Division. 2004-2010Neurology Consult Services. USC University Hospital and LAC+USC Medical Center. Neurology Residents and medical students. Two to six months each year. 1991-2008Lecturer, Multiple Sclerosis and Demyelinating Diseases. Year I and Year II Curricula. Medical Students. 1993- 2004Lecturer, Headache and Facial Pain. Year II Curriculum. Medical Students. 1994-1997Lecturer, Neurology Required Clinical Clerkship, Demyelinating Diseases – Immunopathogenesies, Diagnosis, and Management. Twice monthly, 1999-2007Lecturer, Neurology Residency Curriculum, Immunotherapeutics for Neurological Conditions, 2002-2009Lecturer, Neurology Required Clinical Clerkship, Bioethical issues in neurological care. 1-2/month, 2009-Specific Administrative ResponsibilitiesUSC School of MedicineMember, Dean's Committee on Neurology Curriculum. 1991-2000Member, Board of the Department of Psychiatry, 1995-1999Member, Publications Board. 1996-1999Member, Institutional Review Board, 2003- 2009Vice Chair, USC Health Sciences Institutional Review Board, 2005- 2009USC PhysiciansMember, Planning/Marketing/Contracting Committee. 1993-1998Member, Credentialing, Privileging, and Peer Review Subcommittee. 1994-1999Associate Medical Director, USC CARE. 1996-2000Chair, USC Care Credentials Committee. 1996-1999USC Care, Inc. Medical Informations Subcommittee. 1996-1998USC Care, Inc. Clinical Practice Committee. 1996-2000Operations Committee. 1996-2000Chair, Joint Managed Care and Contracting Subcommittee.1996-1999Chair, MediCal Managed Care Task Force. 1996-1998Chair, USC Doctors at Work Advisory Board. 1996-1998USC University HospitalChair, Credentials Committee. 1996-1999Member, Urgent Admissions Task Force. 1996-1998Member, Medical Executive Committee. 1996-1999USC University Affiliates, IPA Inc.Quality Management and Utilization Management Committee. 1996-1998Community ServiceAdat Ari El Synagogue. North Hollywood, California.Member, Religious Practice Committee, 1996-2005Selected presentations 1991 – present: Lectures and presentations – on request(Professional Background - Continued)Society Presentations Immune mediated clearance of JHM virus from the CNS. Presentation and poster at the 3rd International Coronavirus Symposium. Asilomar, California. 1986 Characterization of monoclonal antibodies to human coronavirus OC43. Presentation and poster at the 3rd International Coronavirus Symposium. Asilomar, California. 1986 Complications of lumbar puncture for meningitis in the age of the CT scan: A five-year retrospective analysis of practice patterns at a large county hospital. Presentation at the American Academy of Neurology Annual Conference, 1992Chairman, National Multiple Sclerosis Society Clinical Advisory Board, Annual Meeting, AAN, April 2003, Honolulu, HawaiiPlenary speaker, 4th Annual Scientific Conference, Chinese Neurological Society, Chongqing, China, November 2005Who me: Ethical issues in multiple sclerosis clinical research. Keynote speaker, National Multiple Sclerosis Regional Annual Meeting, May 2008.Other Significant Employment or ActivitiesOrganizer and Director, USC Clinic for the Performing Artist. Los Angeles, California. 1992-1994Director, USC Multiple Sclerosis and Immunologic Disorders Clinic. Los Angeles, California. 1993-1998. Re-established as the MS Comprehensive Care Center at USC University Hospital. 1998-2010Physician Specialist, Neurology Service. LAC+USC Medical Center. Los Angeles, California. 1991-2010Attending Neurologist and full-time staff. USC University Hospital. Los Angeles, California. 1991-2010Vice President, Kachuck Enterprises, Inc., 2005-2010CEO, Kachuck Enterprises, Inc., 2010 – We own 300 acres, and manage 460 acres of avocado groves in Valley Center, CA, are partners with Henry Avocado, a packing, contract sales and shipping company in Escondido, CA, and act as general partner for real estate investments. Gross annual income $5-7,000,000.Personal InterestsPiano and synthesizer solo and ensemble performance (see YouTube channel); music compositionNeurobiology of evolutionary and self psychology, applied to medical practice and to Jewish theologyD.Society MembershipsFounding Member, USC School of Medicine Student Committee for Student Research. 1984Co-President, California Student Association for Family Practice. 1986-1987Student Representative, Committee on Resident and Student Affairs, California Academy of Family Physicians. 1986-1987Member, Los Angeles Society for the Neurological Sciences. 1989-1996Member, Clinical Advisory Committee, Multiple Sclerosis Society, Southern California Chapter. 1995-2003Member, Governing Board, National MS Society, Southern California Chapter, 1999-2003Chairman, Clinical Advisory Board, National MS Society, Southern California Chapter, 1999-2003Member, National Council of Clinical Advisory Board Committee Chairs, National MS Society, 2003-.Member, Honorary Committee, Multiple Sclerosis Society Annual Dinner of Champions. 1994-Member, Nancy Davis Consortium in the Race to Erase MS, 1999-Member, American Medical Association. 1983-Member, American Academy of Neurology. 1989-E.ConsultantshipsEditorial Board, American Music Teacher. 1993-1995Member, MDs On Line for MS 1994-1998Catalyst Communications. 1994-1997Consultant, FHP Life Assurance Company. 1994Consultant, Advisory Panel and Speaker’s Bureau, Biogen/ Biogen Idec 1996-Consultant, Advisory Panel and Speaker’s Bureau, Teva/ Teva Neuroscience 1995-Consultant, Advisory Panel and Speaker’s Bureau, Berlex 1995-Consultant and Speakers Bureau on Neutralizing Antibodies Against Interferons in MS, Athena Neurosciences, 2002-Consultant, Advisory Panel and Speaker’s Bureau, EMD Serono, 2002-Consultant, Advisory Panels, 2004-present, and Speaker’s Bureau, 2010-, Acorda Therapeutics,Consultant, Advisory Panels, 2008-present, and Speaker-s Bureau, 2010-, NovartisReviewer, Annals of NeurologyReviewer, Journal of NeuroscienceReviewer, Neurology, 2004-Reviewer, Pharmacoepidemiology and Drug Safety, 2005-Reviewer, Contemporary Clinical Trials, 2005-Reviewer, J Inflammation Research, 2010-Laboratory Medical Director, Glycominds, Inc., 2010-2012F.Research Activities at USCComplete BibliographyAppendedMajor Areas of Research InterestImmunomodulation in multiple sclerosis therapeuticsEthical aspects of clinical researchEvolutionary analytic psychoneurologyResearch Trials Active as of May 2010InternalImmunomodulation in Pregnant and Post-Partum Women with MS[Co-Investigator]Nancy Davis Foundation/National MS Society2002-2010ExternalTEVA 9004: Follow-up study of the long-term, double-blind, placebo-controlled multicenter Phase III study to evaluate the efficacy and safety of Copaxone in patients with relapsing-remitting multiple sclerosis. [PI]TEVA Neuroscience1994-2010MS-F202EXT/ MS-F203EXT: Open-label extension studies to evaluate the safety, tolerability and activity of oral Fampridine-SR in Subjects with Multiple Sclerosis [PI]Acorda Therapeutics2003-2010F204/F204EXT : Double Blind, Placebo-controlled, 13-week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Multiple Sclerosis {PI]Acorda Therapeutics2007-2010The “TOUCH?” Study: A Post-registration study to evaluate the safety and tolerability Tysabri? in the treatment of relapsing forms of multiple sclerosis [PI]Sponsor: Biogen Idec2007-2010ONWARD: A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Safety Tolerability and Efficacy Study of Add-on Cladribine Tablet Therapy with Rebif? New Formulation in Multiple Sclerosis Subjects with Active Disease [PI]Sponsor: EMD Serono, Inc2007-2010Research Grants CompletedInternal:Analysis of instrumental technique and performance-related injuries using a MIDI-acquired performance database.Yamaha Corporation Development Grant1992-1993Pilot Project: Disease management in a Center of Excellence for Comprehensive Care in Multiple SclerosisPhysician initiated TrialTenet/USC University Hospital1998-2000QueensCare Foundation Grant: Creation of MS Comprehensive Care CenterQueensCare Foundation Charitable Division2000-2003Drown Foundation Grant: Creation of MS Comprehensive Care Center of Excellence – DatabaseJoseph Drown Foundation2000-2001Multiple sclerosis and estrogen: Lifelong estrogen exposure in disease course and cognition. National Multiple Sclerosis Society Fellowship. 7/1/2000-6/30/2002Investigator Initiated Research: T Cell Frequency Trial: Changes in Frequency and reactivity of T Cells specific of myelin antigens during interferon Beta 1-A (Avonex) treatment. Biogen, Inc.1999- 2002Investigator Initiated Research: Combined Avonex-Novantrone Therapy in Multiple Sclerosis [CANTIMuS]; An open-label safety trial combining mitoxantrone (NovantroneR induction once monthly for six months, and interferon beta-1a (AVONEXR) 6M IU weekly as intramuscular injection, for worsening relapsing-remitting multiple sclerosis.Biogen, Inc.2002-2005T Cell Vaccine: A Phase II, Double Blinded, Clinical Trial for Secondary-Progressive Multiple Sclerosis. NINDS (1 R01 NS38213-01A1) and the National MS Society (RG 3021A1/1) [Co-Investigator]1999-2007External:TEVA 9001: Double-blind, placebo-controlled multicenter Phase III study to evaluate the efficacy and safety of Copaxone in patients with relapsing-remitting multiple sclerosis (co-PI)Teva USA1991-1994A double-blind placebo-controlled, multi-center study of oral myelin (Myeloral?) in the treatment of early relapsing-remitting multiple sclerosis.AutoImmune Inc.1993-1997IMPACT Trial: Interferon Beta-1a (Avonex) in secondary progressive multiple sclerosis.Biogen, Inc.1998-2000PROMiSe TRIAL: Multi-National, Multicenter Double-Blind Placebo-Controlled Study to Evaluate the Efficacy, Tolerability & Safety of Glatiramer Acetate (CopaxoneR) for Injection in Primary Progressive Multiple Sclerosis.Teva Marion Partners./ Teva Neuroscience1999-2003EVIDENCE Trial: Open label, randomized, multicenter, comparative, parallel group study of Rebif 44 mcg administered three times per week by subcutaneous injection, compared with Avonex? 30 mcg administered once per week by intramuscular injection in the treatment of relapsing-remitting multiple sclerosis.Serono, Inc.2000-2001RENEW Trial: Prospective, open-label tolerability and safety monitoring study of Novantrone in a selected cohort of multiple sclerosis patients.Immunex Corporation2002-2005AIMS: A multicenter, Phase IV, Randomized, Open-Label Study to compare the efficacy of two therapies (Acetaminophen & Prednisone) in the management of flu-like symptoms associated with Avonex (Interferon beta 1a) Treatment in patients with relapsing remitting multiple sclerosis.Biogen, Inc.2002-2003GLANCE: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Safety Study of Natalizumab in Combination with Glatiramer Acetate (GA) in Subjects with Relapsing-Remitting Multiple Sclerosis (MS)Mellen Center/Biogen2003-2004MS-F202: Double Blind, Placebo-controlled, 20-week, Parallel Group Study to Evaluate Safety, Tolerability and Activity of Oral Fampridine-SR in Subjects with Multiple SclerosisAcorda Therapeutics, Inc.2003-2004SENTINEL Trial: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Safety and Efficacy of Natalizumab When Added to Avonex, in Subjects with Relapsing Remitting MS [PI]Biogen, Inc./?lan Pharmaceuticals2002-2005Phase II Open-Label Multi-Center Safety and Efficacy study of Oral Recombinant Ovine Interferon Tau (roIFN??Administered daily in Patients with Relapsing-Remitting Multiple Sclerosis [PI]Nancy Davis Consortium/Pepgen Corporation2002-2005[C-1808] An Open-label, Multicenter Extension Study to Evaluate the Safetyand Tolerability of Natalizumab in Subjects with Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803. [PI]Biogen Idec, Inc2004-2006An fMRI Study Of Treatment Optimization Recommendations Comparing Patients Continuing Treatment With Glatiramer Acetate 20 mg qd SC (Copaxone?) To Those Randomized To IFN-β-1a 30 mcg qw SC (Avonex?) In A Multicenter Study Of Patients With Relapsing Remitting Multiple Sclerosis Currently On Disease-Modifying Therapy [PI]Sponsor: Neurognostics, Inc. and Biogen Idec2008 RITUXIMAB (RITUXAN?) TREATMENT IN PRIMARY PROGRESSIVE MS: A Phase II/III randomized, double-blind, parallel-group placebo controlled multicenter study to determine safety and efficacy of an anti-B cell monoclonal antibody in adults with primary progressive MS (sub-investigator).Sponsor: Genentech2006-2007Double Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis [co-PI]Sponsor: Forest Pharmaceuticals2007-2009A Phase I, Randomized, Placebo-Controlled, Crossover, Target Validation Study of CP-122,721 in Subjects with Neurogenic Detrusor Overactivity [co-PI]Sponsor: Pfizer, Inc2007-2009A randomized, multicenter, two-arm, 12-week phase IIIb study to evaluate Quality of Life (QoL) measures in relapsing Multiple Sclerosis subjects who are transitioning from Rebif (Interferon beta-1a) to Rebif New Formulation (RNF) [co-PI]Sponsor: EMD Serono, Inc2007-2009A randomized, multicenter, two arm, open label, 12 week phase IIIb study to evaluate the tolerability of Rebif (New Formulation) (Interferon (IFN) beta-1a) and Betaseron (Interferon (IFN) beta-1b) in interferon-na?ve subjects with relapsing remitting multiple sclerosis; followed by a single-arm, 24 week, Rebif? (New Formulation)-only safety extension [co-PI]Sponsor: EMD Serono, Inc2007-2009STAYCIS --“A Randomized Double Blind Place-Controlled Multi Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients with Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (MS)” [PI]Immune Tolerance Network/NIAID2006-2010BIBLIOGRAPHYPeer ReviewPublishedSteinberg, A., Fitten, L.J. and Kachuck, N.J. Patient participation in treatment decision-making in the nursing home: The issue of competence. The Gerontologist 26(4): 362-366, 1986.Fleming JO, Keck JG, Wei T, Kachuck NJ, Stohlman SA. Characterization of monoclonal antibodies to human OC43. Advances in Experimental Medicine & Biology. 218:517-20, 1987.Kachuck, N.J. and Weiner, J.P.: Cross-reactive antibodies are demonstrated against the therapeutic interferons. Neurol. Network Commentary , Jan, 1999.[Member, MS Study Group]. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner, LP, Wolinsky JS, and the MS Study Group. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 50(3):701-8, 1998 Mar.Johnson KP. Brooks BR. Ford CC. Goodman A. Guarnaccia J. Lisak RP. Myers LW. Panitch HS. Pruitt A. Rose JW. Kachuck N. Wolinsky JS. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Multiple Sclerosis. 6(4):255-66, 2000 Aug[Member, MS Study Group] Wolinsky JS. Narayana PA. Johnson KP. Multiple Sclerosis Study Group and the MRI Analysis Center. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis. 7(1):33-41, 2001 Feb.Weiner LP. Kachuck NJ. Gilmore W. Lund B. Immunological aspects of secondary progressive multiple sclerosis. Multiple Sclerosis. 8(1):83-4, 2002 Feb[Member of Consensus Panel]. Herndon RM, Coyle PK, Murray TJ, Wolinsky JS. Report of the consensus panel on the new international panel guidelines for diagnosis of MS. Intl J MS Care 4(4):170-173, Wtr 2002. [Member, Study Group] Panitch H, Goodin DS, et al., for the EVIDENCE Study Group and the University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon β-1a treatment regimens in MS. Neurology 59:1496-1506, 2002.Frohman EF, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Fillipi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH. The Utility of MRI in suspected MS. Report of the therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003;61:602-611[Member, Study Group] Wolinsky JS, the PROMiSe Study Group. The diagnosis of primary progressive multiple sclerosis. J Neurol Sci 2003; 206:145-152.Lund, B.T., Ashikian, N, Gilmore, W., Burnett, M., Kachuck, N.J. & Weiner, L.P. (2004).? CXCL8 (IL-8) expression is significantly increased in Multiple Sclerosis.? Clinical and Investigative Medicine. 27: 160C.Lund, B.T., Ashikian, N, Ta, H.Q., Chakryan, Y., Manoukian, K., Groshen, S., Gilmore, W., Cheema, G.S., Stohl, W., Burnett, M.E., Ko, D., Kachuck, N.J. & Weiner, L.P. (2004).? Increased IL-8 expression in patients with Multiple Sclerosis.? Journal of Neuroimmunology, 155(1-2):161-71, 2004 Oct.Lund BT, Huy QT, Ashikian N, Kachuck NJ. The Frequency of MBP and PLP, but not MOG, Specific T Cells is Reduced in MS Patients Treated with Intramuscular Interferon-b1a: Correlation with Changes in Th1 and Th2 Cytokine Expression. Abstract. Annals of Neurology Supplement, October, 2004 Annual Meeting, American Neurological Association, Toronto, Canada.Kachuck, N. (2005) Challenges and Opportunities: What we are learning from the natalizumab experience. Expert Rev Neurotherapeutics 5(5):605-615.Bar-Or, A, Vollmer T, Antel J, Arnold DL, Bodner CA, Campagnolo I, Gianettoni, J, Jalili F, Kachuck N, Lapierre Y, Niino M, Shi F-D, Utz PJ, Valone F, Weiner L, Steinman L, Garren H. Induction of Antigen-Specific Tolerance in Multiple Sclerosis after Immunization with DNA Encoding Myelin Basic Protein in a Randomized, Placebo-Controlled Phase 1/2 Trial Arch Neurol.2007;64(10):(doi:10.1001/archneur.64.10.nct70002)Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F202 Study Group. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology. 2008 Oct 7;71(15):1134-41. Epub 2008 Jul 30.Minagara A, Murray TJ; PROOF Study Investigators. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF. Current Med Res Opin. 2008 Apr;24(4):1049-55. Epub 2008 Feb 29.Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009 Feb 28;373(9665):732-8.Kachuck N, Racke M. Monitoring disease progression: incorporating MRI and new modalities in multiple sclerosis clinical decision making. Johns Hopkins Advanced Studies in Medicine. 2009, 8(8):266-273Goodman A, Rossman H, Bar-Or A, et al, GLANCE Investigators. GLANCE: Results of a phase 2, randomized, double-blind, placebo controlled study. Neurology 2009;72:806-812.Kachuck N. Reframing the conflicts of interest debacle: academic medicine, the healing alliance, and the physician’s moral imperative. Journal of Medical Ethics 2009; 35:526-527.Kachuck N. Expert Opinion: Sustained release oral Fampridine in the treatment of multiple sclerosis. Expert Opinion in Pharmacother 2009; 10(12): 1-11.Radue EW, Stuart WH, Calabresi PA, Convfavreux C, Galetta, SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, SENTINEL Investigators. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci 2010 May 15;292(1-2):28-35. Epub 2010 Mar 16. Ford F, Goodman A, Johnson K, Kachuck N, et al. Continuous Long-term Immunomodulatory Therapy in Relapsing Multiple Sclerosis: Results from the 15-year Analysis of the US Prospective Open-label Study of Glatiramer Acetate. Multiple Sclerosis 2010 Mar;16(3):342-350Conway J, Kachuck N. Ethics case and discussion. Continuum Series, Demyelinating Disease, Fall 2010.Goodman AD, Brown TR, Edwards KR, Shapiro RT; Cohen R, Marinucci LN, Blight AR, MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010 Oct;68(4):494-502.Kachuck NJ. Managing conflicts of interest and commitment: academic medicine and the physician’s progress. Journal of Medical Ethics 2011 Jan;37(1):2-5.Kachuck NJ. Registries, research, and regrets: is the FDA's post-marketing REMS process not adequately protecting patients? Ther Adv Neurol Disord. 2011 Nov;4(6):339-47Kachuck NJ. When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis. Neuropsychiatr Dis Treat. 2011;7:197-208. Epub 2011 Apr 19Limmroth V, Putzki N, Kachuck NJ. The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Therapeutic Advances in Neurological Disorders 2011;4:281-296Waubant E, Pelletier D, Mass M, Cohen JA, Kita M, Cross A, Bar-Or A, Vollmer T, Racke M, Stüve O, Schwid S, Goodman A,?Kachuck?N, Preiningerova J, Weinstock-Guttman B, Calabresi PA, Miller A, Mokhtarani M, Iklé D, Murphy S, Kopetskie H, Ding L, Rosenberg E, Spencer C, Zamvil SS; On behalf of the ITN STAyCIS Study Group. Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study. Neurology 2012 Apr 10;78(15):1171-1178. Epub 2012 Mar 28.Kachuck NJ. Medical decisions are not just about the facts: what a life-threatening virus can teach us about empathy, psychology and the practice of neurology. Neurology Clinical Practice, 2012;2:122-128.Kachuck NJ. Letter to Editor in regards to “The academic medical center in a disrupted world”. Pharos. Autumn 2015, pp 62-64.Kachuck NJ. Controversies in neurology. Physician as moral “fifth column”: the clinician and the translational medicine investor. Neurology Clinical Practice, in pressKachuck NJ. Reasons beyond the science: why we lack biomarkers for multiple sclerosis diagnosis and treatment. Multiple Sclerosis and Related Disorders, in press.UnpublishedKachuck, N.J. and Scolaro, M.S.: A retrospective study on the efficacy of treatment of low back pain by a hospital based pain clinic. Research Fellowship awarded by the St. Vincent Hospital Pain Management Center/Robert Wood Johnson Foundation.Showalter S, Kachuck NJ, Buckwalter G. Multiple sclerosis and estrogen: Lifelong exposure in disease course and cognition. ChaptersFleming, J.O., Keck, J., Wei, T., Kachuck, N. and Stohlman, S.: Characterization of Monoclonal Antibodies to Human Coronavirus OC43. In: Coronaviruses. (M.M.C. Lai and S.A. Stohlman, eds.) Plenum Press: New York. 1987. pp. 517-520.Sussman, M.A., Kachuck, N. and Stohlman, S.A.: Immune Mediated Clearance of JHM Virus from the CNS. In: Coronaviruses. (M.M.C. Lai and S.A. Stohlman, eds.) Plenum Press: New York. 1987.Kachuck, N.J. and Weiner, L.P.: Viral Infection and the Chronic Fatigue Syndrome. In: Current Neurology 13. (S.A. Appel, ed.) Mosby-Year Book. Inc.: New York. 1993. pp. 289-320.Kachuck, N.J. and Weiner, L.P.: Viral Meningitis and Encephalitis. In: Conn's Current Therapy. (R.E. Rakel, Ed.) 1994. pp. 885-891.Weiner, L.P. and Kachuck, N.J.: CNS Infections. In: Outcomes in Neurological and Neurosurgical Disorders. (M. Swash and J. Weldon, Eds.)INTERVIEWS:1.Haughn Z . Therapeutics Q&A: Dalfampridine in clinical use. Practical Neurology | March/April 2010, pg 32-33 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download